Tenecteplase Before Thrombectomy for Large Vessel Blockage Stroke
Compares tenecteplase with alteplase before clot removal in adults with acute ischemic stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had a stroke caused by a blocked large brain artery within 4.5 hours, and who can have clot-removal treatment.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke with a blocked large artery (ICA, ACA, PCA, M1 or M2 of the MCA, or basilar artery) seen on CTA or MRA. Symptoms started 4.5 hours ago or less, counted from when the person was last known to be well.
- Earlier treatment
- Heparin in the past 24 hours, and direct thrombin or direct Factor Xa inhibitors in the past 48 hours, are not allowed.
- Biomarker or test result
- Before the stroke, the mRS score was 2 or lower. Blood glucose must be between 2.8 and 22.2 mmol/L (50–400 mg/dL). For people on oral anticoagulants, INR must be 1.7 or lower and PT 15 seconds or lower. Platelet count must be 100 × 10⁹/L or higher.
Main reasons for not taking part
- Bleeding in the brain or a history of brain bleeding
- Severe head injury or stroke in the past 3 months
- Major surgery in the past 2 weeks
- Uncontrolled high blood pressure (above 180/100 mmHg)
- Pregnancy
Read by machine on 12 November 2026.
Where in China
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaContact: Xiuhai Guo, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xuanwu Hospital, Beijing
- Trial code
- NCT06658197
- Record updated
- 9 April 2026
- Original description
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.Read full original descriptionShow less
Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusive Stroke(TNK-LVO) :a Phase 3, Multicentre, Open-label, Randomised Controlled Trial
A phase III, multicentre, prospective, randomised, open-label, blinded-endpoint clinical trial will evaluate two thrombolytic agents for the treatment of acute large vessel occlusion stroke within 4.5 hours from symptoms onset: intravenous tenecteplase bridging mechanical thrombectomy vs. intravenous alteplase bridging mechanical thrombectomy.
Inclusion: Age is ≥18 years; AIS symptom onset ≤4.5 hours, onset time refers to the time the patient was last known to be well. (Recommendation time from thrombolysis to puncture within 60 minutes); Arterial occlusion of the internal carotid artery (ICA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery on computed tomography angiography (CTA) or magnetic resonance angiography (MRA); Prestroke mRS score ≤2; Informed consent from the patient or legally authorised representative.
Exclusion: Intracranial or intraspinal surgery within the past 3 months; Major surgery within the past 2 weeks; Heparin treatment received within the past 24 hours; Use of direct thrombin inhibitors or direct Factor Xa inhibitors within the past 48 hours; Patients diagnosed with hemorrhagic stroke (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.) or other related conditions identified by CT; History of intracranial hemorrhage; History of severe head trauma or stroke within the past 3 months; Gastrointestinal or urinary tract bleeding within the past 3 weeks; Active visceral bleeding; Uncontrolled hypertension despite active antihypertensive treatment: Systolic Blood Pressure > 180 mmHg or Diastolic Blood Pressure > 100 mmHg; Any terminal illness where life expectancy is considered not to exceed 1 year; Any condition where, in the judgment of the investigator, the study treatment might pose a risk to the patient or affect the patient's participation in the study; Known allergy to the active ingredients (Alteplase, Tenecteplase) or any excipients; Acute hemorrhagic tendency, including platelet count < 100 × 10⁹/L or other conditions; For patients on oral anticoagulants: INR > 1.7 or PT > 15 seconds; Blood glucose < 2.8 mmol/L or > 22.2 mmol/L; Contraindication to imaging examinations involving contrast agent injection; Patients presenting with clinical symptoms of coma (NIHSS Score Item 1a = 3); Intracranial tumor, arteriovenous malformation, or giant intracranial aneurysm; Aortic arch dissection; Arterial puncture at a non-compressible site within the past week; Hypodensity affecting > 1/3 of the middle cerebral artery territory or an equivalent proportion of the basilar artery territory on non-contrast CT; Rapidly improving symptoms as determined by the investigator; Participation as a subject in another research study within the past 30 days; Pregnant women.